Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A...
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
About this item
Full title
Author / Creator
Pineda, Estela , Salud, A , Vila-Navarro, E , Safont, MJ , Llorente, Beatriz , Aparicio, J , Vera, R , Escudero, P , Casado, E , Bosch, C , Bohn, U , Pérez-Carrión, R , Carmona, A , Ayuso, JR , Ripollés, T , Bouzas, R , Gironella, M , García-Albéniz, X , Feliu, J and Maurel, J
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Despite initial responsiveness, acquired resistance to both bevacizumab and chemotherapy in metastatic colorectal cancer is universal. We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-M...
Alternative Titles
Full title
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d64f661229de49f9828a4a293adb26af
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d64f661229de49f9828a4a293adb26af
Other Identifiers
ISSN
1010-4283
E-ISSN
1423-0380
DOI
10.1177/1010428317705509
